xpeer logo
© Xpeer 2026 All rights reserved
Privacy Policy - Terms of Use - Help

Register now for free!

Over 100,000 doctors have already joined Xpeer — register now to find out why, and get instant access to this course and many more.

I already have an account
Course Preview

The latest in lung cancer: insights from ASCO 2026 – Part 2

4.8

Accredited (Credits: 0.5)
Free
29min
Audio: English

Synopsis

Stay at the forefront of lung cancer care with an expert-led look at the most important research unveiled at the American Society of Clinical Oncology (ASCO) 2026. Discover how emerging approaches in targeted therapy and immunotherapy may reshape treatment across non-small-cell lung cancer (NSCLC) and relapsed small-cell lung cancer (SCLC).

This activity is supported by an independent support grant from IASLC

Objectives

After completing this activity, participants should be better prepared to:

  • Assess emerging therapies for NSCLC with actionable genomic alterations
  • Analyse novel therapeutic options beyond chemotherapy for relapsed SCLC
  • Describe the safety and efficacy of emerging immunotherapy combinations for actionable genomic alteration-negative NSCLC

Accreditation

This course is accredited with 0.5 ECMEC credits valid in 26 countries. To claim your credits take the evaluation (satisfaction survey and evaluation questionnaire). You have 3 attempts for the evaluation. You need to pass the evaluation with a sufficient score to validate the course. Your diploma is issued instantaneously and sent to your email.

See more information on the accreditation at: Accreditation

Duration

29min

Target audience

Medical oncology, Oncology, Doctor / Physician, Nurse, Advanced Practice Nurse, Doctor Assistant / Physician Assistant

Authors

Dr. Kaushal Parikh

Kaushal Parikh, MBBS, is a Thoracic Medical Oncologist at Mayo Clinic in Rochester, Minnesota.

Conflicts of interests statement:

Research funding from: Dragonfly, Merck, Verastem, Vividion. All research funding goes to the recipient´s institution. Consultant for: AstraZeneca, ImmunityBio, Regeneron, Rigel Therapeutics, Takeda.

Testimonials

“Excellent platform to stay up to date and keep learning throughout your professional career. I recommend it to all my colleagues.”

Omar I. onTrustpilot

Spain

“Xpeer is a magnificent platform for healthcare professionals, where you can gain knowledge from a scientific and highly up-to-date perspective across various medical specialties.”

Wil A. onTrustpilot

Netherlands

“I've taken several courses on Xpeer and they've been very useful. The format is very dynamic, allowing you to watch the videos in your free time since they're no longer than 15 minutes. The topics are very current.”

Francisco P. onTrustpilot

Spain

Read more reviews onTrustpilot

FAQs

What you will learn

ASCO updates: part 2

  • Actionable genomic alteration-negative advanced NSCLC
  • Questions and answers

Accreditation - Evaluation

  • Satisfaction survey
  • Multiple-choice test

Register now for free!

Over 100,000 doctors have already joined Xpeer — register now to find out why, and get instant access to this course and many more.

I already have an account